Two antibodies attacking different targets might overcome resistance
In the long human struggle against infectious disease, the search for treatment has always run alongside the search for prevention. In late March 2021, three pharmaceutical companies — Eli Lilly, Vir Biotechnology, and GlaxoSmithKline — offered a measured but meaningful signal: a pairing of two experimental monoclonal antibodies reduced persistent viral load in mild-to-moderate COVID-19 patients by 70 percent at day seven, suggesting that combination therapy might one day fill the gap between vaccination and recovery. The finding is early, the road to approval long, but the direction is hopeful.
- With vaccines accelerating but treatment options still scarce, the pressure to find effective antivirals for COVID-19 patients — especially those ineligible for vaccines — remained urgent in early 2021.
- The combination of bamlanivimab and VIR-7831 disrupted the virus through two distinct mechanisms, raising the possibility that attacking from multiple angles could overcome resistance and amplify results.
- A 70 percent reduction in viral load at day seven compared to placebo gave the trial its headline, but the Phase 2 scale — a few hundred patients — meant the result was promising, not conclusive.
- Markets barely flinched: Eli Lilly dipped 0.4 percent, Vir edged up 0.3 percent, a muted response that reflected investor wisdom about the distance between early data and regulatory approval.
- The trial is set to expand toward 1,000 patients, with Phase 3 confirmation the necessary next step before this combination could realistically reach the patients who need it most.
On a Monday in late March 2021, Eli Lilly, Vir Biotechnology, and GlaxoSmithKline announced that combining two experimental antibody treatments had produced a striking early result: a 70 percent reduction in persistently elevated viral load at day seven among COVID-19 patients, compared to those who received a placebo. The trial enrolled adults with mild to moderate illness who were not considered high-risk — a group where early intervention might prevent the disease from worsening.
The logic behind the combination was straightforward: two monoclonal antibodies, each targeting the virus through different mechanisms, might prove more powerful together than either alone, and less vulnerable to viral resistance. Eli Lilly's Chief Scientific Officer called the virology data encouraging and described the pairing as a promising treatment candidate.
Monoclonal antibodies work differently from vaccines — rather than training the immune system, they are laboratory-engineered proteins that bind directly to the virus and neutralize it. The combination approach was designed to test whether that dual attack offered a meaningful advantage.
The Phase 2 results, while positive, represented only an early chapter. The trial was expected to grow to as many as 1,000 participants, and Phase 3 trials — larger, more diverse, and required for regulatory consideration — would need to confirm what Phase 2 suggested. Markets reflected that caution, with share movements barely registering across all three companies.
The announcement arrived at a moment when vaccination was gaining momentum in wealthier nations, yet COVID-19 remained a global threat and treatment options remained thin. For patients who could not be vaccinated or who developed infections despite vaccination, an effective early-stage antiviral would represent something the pandemic toolkit still lacked. Whether this combination would become that option remained, for now, an open and carefully watched question.
Three major pharmaceutical companies announced Monday that a combination of two experimental antibody treatments had substantially reduced the viral load in COVID-19 patients during early testing. Eli Lilly, Vir Biotechnology, and GlaxoSmithKline reported results from a Phase 2 trial pairing Lilly's bamlanivimab with Vir's VIR-7831, showing a 70 percent drop in persistently elevated viral levels at day seven when compared to patients who received a placebo.
The trial focused on adults with mild to moderate COVID-19 who were not at high risk for severe disease—a population where early intervention with antivirals might prevent progression. The companies designed the study to test whether combining two different monoclonal antibodies, each targeting the virus through slightly different mechanisms, would prove more effective than either drug alone. The result suggested the pairing had merit. "These virology data support our belief that bamlanivimab and VIR-7831 together could be a promising option for COVID-19 treatment," said Dr. Daniel Skovronsky, Eli Lilly's Chief Scientific Officer, in a statement accompanying the announcement.
Monoclonal antibodies represent one of several therapeutic approaches being pursued to treat COVID-19. Unlike vaccines, which train the immune system to recognize the virus, these laboratory-made proteins are designed to bind directly to the virus and neutralize it or mark it for destruction. The appeal of a combination approach lies in the possibility that two antibodies attacking different viral targets might overcome resistance or simply work more powerfully together than separately.
The trial is expected to eventually enroll as many as 1,000 patients, a substantial expansion from the Phase 2 cohort that generated these initial results. Phase 2 trials typically involve a few hundred participants and are designed primarily to assess whether a treatment shows promise and to identify the right dose. The next step would be larger Phase 3 trials, which are needed to confirm efficacy and safety in a broader population before regulatory agencies consider approval.
Stock market reaction to the news was muted. Eli Lilly shares dipped 0.4 percent in premarket trading, while Vir edged up 0.3 percent. GlaxoSmithKline, which is providing manufacturing and distribution support for the combination, saw minimal movement. The modest market response reflected the reality that Phase 2 results, while encouraging, do not guarantee success in the larger trials ahead. Investors and clinicians alike understand that many promising early-stage treatments fail to maintain their advantage when tested in larger, more diverse populations.
The timing of the announcement, in late March 2021, came as vaccination campaigns were accelerating across the United States and other wealthy nations, yet COVID-19 remained a significant public health threat globally. Treatment options remained limited, particularly for patients who could not receive vaccines or who developed breakthrough infections. A safe and effective antiviral therapy, especially one that could be administered early in illness, would fill an important gap in the pandemic response toolkit. The companies' next move would be to expand enrollment and gather the additional data needed to determine whether this combination approach could earn regulatory approval and ultimately reach patients.
Notable Quotes
These virology data support our belief that bamlanivimab and VIR-7831 together could be a promising option for COVID-19 treatment— Dr. Daniel Skovronsky, Chief Scientific Officer, Eli Lilly
The Hearth Conversation Another angle on the story
Why combine two antibodies instead of just using one?
Each antibody targets a different part of the virus. Together, they might overwhelm the virus's ability to escape, or simply work more powerfully in tandem. It's a hedge against resistance and a test of synergy.
What does a 70 percent reduction in viral load actually mean for a patient?
It means less virus circulating in their bloodstream at day seven. Whether that translates to fewer symptoms, faster recovery, or fewer hospitalizations—that's what Phase 3 will need to show. Early virology data is promising, but it's not the same as clinical benefit.
Why focus on low-risk patients if the real problem is severe disease?
Low-risk patients are easier to study ethically and logistically. But the real hope is that catching the virus early and reducing viral load prevents progression to severe disease in the first place. That's the theory being tested.
How long until we know if this actually works?
Phase 3 enrollment could take months, and the trial itself runs for weeks or months per patient. We're probably looking at late 2021 or 2022 before there's enough data for regulators to make a decision.
Does the stock market's flat reaction mean investors don't believe in this?
Not necessarily. By March 2021, vaccines were already rolling out. Investors may see antibody treatments as a secondary option—useful, but not the primary solution to the pandemic. That changes the commercial calculus.